ERBB2 and breast cancer: The abnormalities in glucose, amino acid, and fatty acid metabolism are also closely linked to HER2 inhibitor therapy in HER2+ BC, and the dysregulated enzymes in these metabolic pathways could be potential markers for the prediction of drug resistance [104].